The Effect of Microglial Cells on Parkinson’s Diseases

Acta Neuropharmacologica ›› 2012, Vol. 2 ›› Issue (4): 28-31.

Previous Articles Next Articles

The Effect of Microglial Cells on Parkinson’s Diseases

^{WEI Wei^1,2 YUAN Yu-he¹ CHEN Nai-hong¹}

1. State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China
2. Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China

Online:2012-08-26 Published:2014-06-27
Contact: 陈乃宏，男，教授；研究方向：神经药理学；Tel: +86-010-63165177，Fax: +86-010-63165177，E-mail: chennh@imm.ac.cn
About author:魏巍，女，硕士研究生；研究方向：神经药理学；E-mail：1375913971@qq.com
Supported by:
国家863计划基金（No.2012AA020303），长江学者和创新团队发展计划(PCSIRT No.IRT1007)，国家自然科学基金（No.81274122、No.81173578），国家国际科技合作项目(No.2010DFB32900)，创新药物研究开发技术平台建设（No.2012ZX09301002-004、No.2012ZX09103101-006），教育部博士点基金重点项目(No.20121106130001)，北京市自然基金重点项目(No.7131013)

Abstract

Abstract: Microglial cells play an essential role in degenerative neurological diseases, including neurodegenerative process of Alzheimer's disease and Parkinson's disease. However, it is yet unclear the exact roles of microglia cells in neurodegenerative diseases plays, although it is known that excessive activation of microglia will ultimately lead to neuronal death. Activated microglia secrete a variety of inflammatory and neurotoxic factors that may aggrevate neurodegenerative diseases. In fact, systemic inflammation is one of the main causes attributable to chronic neurodegenerative diseases related functions decline. In this article, we summarized the role of microglial cells in the pathogenesis of neurodegenerative diseases. In addition, we also discussed new methods and potential therapeutic strategies of neurodegenerative disorders.

Key words: Parkinson's disease, neuroinflammation, microglia

CLC Number:

R965

WEI Wei， YUAN Yu-he， CHEN Nai-hong. The Effect of Microglial Cells on Parkinson’s Diseases[J]. Acta Neuropharmacologica, 2012, 2(4): 28-31.

References

[1] J William Langston. Parkinson's disease: current and future challenges [J]. Neurotoxicology, 2002, 23(4-5): 443-450.

[2] S Papapetropoulos, N Adi, J Ellul. A prospective study of familial versus sporadic Parkinson's disease [J] .Neurodegener Dis, 2007, 4(6): 424-427.

[3] Malu G Tansey, Melissa K McCoy, Tamy C Frank-Cannon．Neuroinflammatory meehanisms in Parkinson’s disease：potential environmentsl triggers, pathways, and targets for early therapeutic intervention [J]．Exp Neurol, 2007, 208(1): 1-25．

[4] Gao Hui-ming，Jiang Jan-wei，Belinda Wilson, et al. Microglial aetivation-mediated delayed and progressive degener-ation of rat nigral dopaminergic neurons：relevance to Parkinson’s disease [J]. J Neurochem, 2002, 81(6): 1285-1297．

[5] A R Carta, L Frau, A Pisanu, et al. Rosiglitazone decreases peroxisome proliferator receptorgamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson’s disease model. Neuroscience, 2011, 27(194): 250–261

[6] Hideyuki Takeuchi, Jin Shi-jie, Wang Jin-yan, et al. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner [J]. Biol Chem, 2006, 281(30): 21362-21368.

[7] Vicki Waetzig, Karen Czeloth, Ute Hidding, et al. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia [J]. Glia, 2005, 50(3): 235-246.

[8] Dennis J Stuehr, Olufunmilayo A Fasehun, Nyoun Soo Kwon, et al. Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenylene-iodonium and its analogs[J]. FASEB, 1991, 5: 98-103.

[9] C S Raman, Li Hui-ying, Pavel Martasek, et al. Crystal structure of constitutive endothelial nitric oxide synthase: A paradigm for pteridine function involving a novel metal center [J]. Cell, 1998, 95(7): 939-950.

[10] Annual J Hobbs, Annie Higgs, Salvador Moncada. Inhibition of nitric oxide synthase as a potential therapeutic target[J]. Annu Rev Pharmacol Toxicology, 1999, 39: 191-220.

[11] W K Kim, Y Kan, D Ganea, et al. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-a production in injured spinal cord and in activated microglia via cAMP-dependent pathway[J]. Neuroscience, 2000, 273: 3622-3630.

[12] Won-Ki Kim, Pil-Geum Jang, Moon-Sook Woo, et al. A new anti-inflammatory agent KL-1037 represses proinflammatory cytokine and inducible nitric oxide synthase (iNOS) gene expression in activated microglia [J]. Neuropharmacol, 2004, 47(2): 243-252

[13] W J Streit, J R Conde, S E Fendrick, et al. Role of microglia in the central nervous system's immune response [J]. Neurol Res, 2005, 27(7): 685-691.

[14] M Reale, C Iarlori, A Thomas, et al. Peripheral cytokines profile in Parkinson’s disease[J]. Brain Behav Immun, 2009, 23(1): 55–63.

[15] K Bendtzen. Why is too little TNF bad? [J]. Cytokine, 1991, 3(6): 636-637.

[16] Richard J Armitage. Tumor necrosis factor receptor superfamily members and their ligands[J]. Curr Opin Immun, 1994, 6(3): 407-413,.

[17] Shi Kun, Wang Dao-de, Cao Xiao-jian, et al. Endoplasmic reticulum stress signaling is involved in mitomycin C(MMC)-induced apoptosis in human fibroblasts via PERK pathway [J]. PLoS One, 2013, 8(3): e59330.

[18] Christoph Richter, Vladimir Gogvadze, Renato Laffranchi, et al. Oxidants in mitochondria:from physiology to disease[J]. Biochim Biophys Acta, 1995, 1271(1): 67-74.

[19] Tomomi Kuwana, Jesse J Smith, Marta Muzio, et al. Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome C [J]. Biol.Chem, 1998, 273(26): 16589-16594.

[20] J M Adams, S Cory. The Bcl-2 protein family: arbiters of cell survival [J]. Science, 1998, 281(5381): 1322-1325.

[21] M S Brassesco, G M Roberto, A G Morales, et al. Inhibition of NF-κB by dehydroxymethylepoxyquinomicin suppresses invasion and synergistically potentiates temozolomide and γ -radiation cytotoxicity in glioblastoma cells[J]. Chemother Res Pract, 2013, 1155: 593020.

[22] Michelle L Block, Luigi Zecca, Jau-Shyong Hong. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms [J]. Nat Rev Neurosci, 2007, 8(1): 57-69

[23] Liu Bin, Du Lina, Jau-Shyong Hong, Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation[ J ]. J Pharmacol Exp Ther, 2000, 293(2): 607-617.

[24] Eiji Hasegawa, Koichiro Takasgige, Tomonari Oishi, et al. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles[J]. Biochem Biophys Res Commun, 1990, 170(3): 1049-1055.

[25] Gao Hui-ming, Hong Jau-shyong, Zhang Wan-qin, et a1. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons [J]. J Neurosci, 2002, 22(3): 782-790．

[26] Gao Hui-ming, Jiang Jan-wei, Belinda Wilson, et a1. Microglial Aetivation-mediated Delayed and Progressive Degener-ation of Rat Nigral Dopaminergic Neurons: Relevance to Parkinson’s Disease, [J]. J Neurochem, 2002, 81(6): 1285-1297．

[27] Gao Hui-ming, Hong Jau-Shyong, Zhang Wan-qin, et al．Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons[J]. J Neurosci, 2002, 22(3): 782-790．

[28] James A Waschek．VIP and PACAP receptor-mediated actions on cell proliferation and survival, [J]. Ann NY Acad Sci, 1996, 805: 290-300．

The Effect of Microglial Cells on Parkinson’s Diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

[1]	王奇. Bushen-Yizhi Formula Inhibits the NLRP3/NFκB Mediated Neuroinflammation and Improves the Motor Dysfunction in a Mouse Model of Parkinson's Disease [J]. Acta Neuropharmacologica, 2018, 8(5): 71-72.
[2]	LIU Cai-hong，WU Xian，TANG Su-su，HONG Hao. Involvement of TGR5 in Aβ-Induced Neurotoxicity in Vivo* [J]. Acta Neuropharmacologica, 2018, 8(4): 11-12.
[3]	WU Xian, LV Yang-ge, TANG Su-Su, HONG Hao. Involvement of TGR5 in Aβ-induced Neurotoxicity in Vivo [J]. Acta Neuropharmacologica, 2018, 8(4): 53-54.
[4]	HUANG Qian，SUN Ming-li，LI Teng-fei，WANG Yong-xiang. Research Progress on Mechanisms Underlying Aconitines Analgesia [J]. Acta Neuropharmacologica, 2017, 7(3): 21-32.
[5]	DU Guan-tao，ZHANG Chun-teng，HONG Hao. Progress on Research of 5-Lipoxygenase in Alzheimer’s Disease [J]. Acta Neuropharmacologica, 2016, 6(5): 39-44.
[6]	HONG Li-mian，JIN Gui-lin，CHU Mei-mei，YU Chang-xi. A Review on the Role of Microglia in Diabetic Neuropathic Pain [J]. Acta Neuropharmacologica, 2016, 6(3): 56-64.
[7]	ZHOU Si-bai, LI Jin-ze, LIU Rui, ZHANG Tian-tai. Recent Development of the Flavonoids on the Treatment of Alzheimer’s Disease [J]. Acta Neuropharmacologica, 2015, 5(1): 51-58.
[8]	CHE Jian-tu, TU Ya, WANG Kong-jiang. Fetuin Attenuates Cerebral lschemic Injury in Rats Associated with Decreases in Macrophage/Microglia and Tumor Necrosis Factor α [J]. Acta Neuropharmacologica, 2012, 2(6): 18-27.